Miacalcic (calcitonin) Important Safety Information from Novartis as approved by the Irish Medicines Board
20 August 2012
Important Safety Information communication from Novartis on calcitonin associated with malignancy – withdrawal of Miacalcic 200IU nasal spray, solution from the market.
Important Safety Information - Miacalcic